Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Alpha-1 antitrypsin deficiency (AATD) (Pi*ZZ) can cause advanced liver fibrosis and cirrhosis in a subset of patients. Transient elastography (TE) to determine degree of fibrosis has been validated in AATD, but is sometimes unavailable. Serum markers of liver fibrosis have not been tested extensively in AATD. Aim was to determine performance of serum markers to exclude significant or advanced fibrosis in Pi*ZZ patients.
Methods: In two cohorts of total 362 Pi*ZZ patients with sera and TE from Leiden and Aachen 2015-2023 enhanced liver fibrosis test (ELF), Aspartate aminotransferase to Platelet Ratio Index (APRI), and fibrosis-4 index (FIB-4) were determined retrospectively, and performance for the evaluation of fibrosis status was assessed using TE as gold standard, calculating area under the receiver operating characteristic curve (AUROC) and negative predictive value (NPV) for excluding significant or advanced fibrosis.
Results: AUROC of APRI was highest for significant and advanced fibrosis in both cohorts (Leiden: 0.854 (95 % CI 0.749-0.958), Aachen: 0.684 (95 % CI 0.605-0.763)), followed by FIB-4. ELF had the lowest AUROC for significant fibrosis. For advanced fibrosis AUROC for ELF was slightly higher than for FIB-4. APRI <0.41 demonstrated the best overall diagnostic performance in excluding advanced fibrosis with NPV of 97 %. The limited number of liver-related clinical endpoints within 4 years were predicted by APRI and FIB-4.
Conclusion: In Pi*ZZ AATD patients APRI below 0.41 or FIB-4 below 1.79 excludes advanced fibrosis/cirrhosis if TE in unavailable, ELF had no additional value. TE remains the preferred method for staging fibrosis in AATD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejim.2025.07.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Linc01271 promotes lipid synthesis and MASLD/MASH progression via miR-149-3p/RAB35 axis.
Cell Mol Life Sci
September 2025
Department of Gastroenterology, The Second Hospital of Shandong University, Jinan, China.
Metabolic associated steatohepatitis (MASH) is a severe form of metabolic dysfunction-associated steatotic liver disease (MASLD) characterized by hepatocellular injury, inflammation, and fibrosis. Despite advances in understanding its pathophysiology, the molecular mechanisms driving MASH progression remain unclear. This study investigates the role of long non-coding RNA Linc01271 in MASLD/MASH pathogenesis, ant its involvement in the miR-149-3p/RAB35 axis and PI3K/AKT/mTOR signaling pathway.
View Article and Find Full Text PDFReduced Predictive Performance of the FIB-4 Index in Chronic Hepatitis B Patients With Concurrent Metabolic Dysfunction-Associated Liver Disease.
J Viral Hepat
October 2025
Technion Israel Institute of Technology, Rappaport Faculty of Medicine, Haifa, Israel.
The coexistence of chronic hepatitis B (CHB) and metabolic dysfunction-associated liver disease (MASLD) gained recognition, but the diagnostic performance of non-invasive markers regarding it remains underexplored. This study aimed to evaluate the utility of the FIB-4 index for fibrosis prediction in CHB patients and investigate its performance in the distinct subgroup of CHB-MASLD. A prospective study from 2021 to 2022 included 109 CHB and 64 CHB-MASLD patients.
View Article and Find Full Text PDFTwo-Decade Trends in MASLD and Its Complications in the Middle East and North Africa (2010-2021).
Liver Int
October 2025
The Global NASH Council, Washington, DC, USA.
Background: The Middle East and North Africa (MENA) region is undergoing demographic shifts potentially increasing metabolic dysfunction-associated steatotic liver disease (MASLD) and its complications. We assessed MASLD prevalence and liver disease burden from 2010 to 2021.
Methods: Data from Global Burden of Disease (GBD), United Nations Population Division and NCD Risk Factor Collaboration covering 21 MENA countries were used for annual percent change (APC) trends per Joinpoint regression.
Serum Proteomic Profile Based on the TGF-β Pathway Stratifies Risk of Hepatocellular Carcinoma.
Liver Int
October 2025
Division of Gastroenterology and Hepatology, Department of Medicine, The Institute for Bioelectronic Medicine, Feinstein Institutes for Medical Research & Cold Spring Harbor Laboratory, Northwell Health, Manhasset, New York, USA.
Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths, primarily due to late-stage diagnosis. In this multicenter study, our goal is to identify functional biomarkers that stratify the risk of HCC in patients with cirrhosis (CP) for early diagnosis.
Methods: Five thousand and eight serum proteins (Somascan) were analysed in Cohort A (477 CP, including 125 HCC).
Joint effects of prognostic nutritional index and skeletal muscle index on prognosis of decompensated cirrhosis: a retrospective cohort study.
Ther Adv Chronic Dis
September 2025
Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Anshan Road 154, Heping District, Tianjin 300052, China.
Background: Liver cirrhosis, characterized by chronic inflammation, is frequently complicated by malnutrition. Nutritional indices, such as the prognostic nutritional index (PNI) and the skeletal muscle index (SMI), calculated as the muscle area quantified via CT scans at the third lumbar vertebra level divided by the square of the patient's height in meters (cm/m), are associated with outcomes in inflammatory diseases.
Objectives: We aimed to evaluate the diagnostic efficacy of the PNI both independently and in combination with the SMI for identifying malnutrition in cirrhosis and to explore their prognostic implications.